2025
EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES
Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES. Urologic Oncology Seminars And Original Investigations 2025, 43: 43. DOI: 10.1016/j.urolonc.2024.12.109.Peer-Reviewed Original ResearchPlasmacytoid urothelial carcinomaNational Cancer DatabaseMedian overall survivalNeoadjuvant chemotherapyUrothelial carcinomaOverall survivalImpact of neoadjuvant chemotherapyResponse to current therapiesCharacterize treatment patternsPrimary treatment typeCox proportional hazards analysisSite of metastasisEvaluate clinical outcomesProportional hazards analysisBorderline statistical significancePT0 rateOS benefitHistological subtypesCancer DatabaseClinical stageClinical outcomesTreatment patternsCurrent therapiesInstitutional experiencePrimary outcomeImpact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non–muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies
Annapureddy D, Taylor J, Kamat A, O'Donnell M, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y. Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non–muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies. European Urology Focus 2025 PMID: 39922753, DOI: 10.1016/j.euf.2025.01.001.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerCarcinoma in situBCG-unresponsive NMIBCBladder-sparing therapyOncological outcomesTumor stageBladder cancer mortalityCancer mortalityAssociated with worse oncologic outcomesPresence of carcinoma in situCarcinoma in situ groupImpact of tumor stageTA groupKaplan-Meier methodPapillary diseaseT1 diseaseRadical cystectomyNo significant differenceClinical stageBladder cancerSurvival differencesRetrospective natureCis groupDisease progressionMetastasis
2024
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial
Iyer G, Tangen C, Sarfaty M, Regazzi A, Lee I, Fong M, Choi W, Dinney C, Flaig T, Thompson I, Lerner S, McConkey D, Rosenberg J. DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. JCO Precision Oncology 2024, 8: e2400287. PMID: 39499893, DOI: 10.1200/po.24.00287.Peer-Reviewed Original ResearchConceptsNeoadjuvant cisplatin-based chemotherapyMuscle-invasive bladder cancerProgression-free survivalDDR alterationsDNA damage response alterationPathological responseBladder cancerDNA damage responseAssociated with pathological responseNeoadjuvant chemotherapy sensitivityPretreatment tumor specimensPathological response rateCisplatin-based chemotherapyDNA damage response genesEstimates of hazard ratiosOverall survivalRadical cystectomyTumor specimensPerformance statusClinical stageChemotherapy sensitivityCox regressionHazard ratioNext-generation sequencingPatientsTrends in breast cancer–specific death by clinical stage at diagnoses between 2000 and 2017
Marczyk M, Kahn A, Silber A, Rosenblit M, Digiovanna M, Lustberg M, Pusztai L. Trends in breast cancer–specific death by clinical stage at diagnoses between 2000 and 2017. Journal Of The National Cancer Institute 2024, 117: 287-295. PMID: 39348186, DOI: 10.1093/jnci/djae241.Peer-Reviewed Original ResearchBreast cancer-specific deathCancer-specific deathBreast cancerStage IAll-cause mortalityTemporal trendsStage I/II breast cancerHormone receptor-positiveNode-negative cancersPrimary tumor typeStage I/II diseaseMetastatic breast cancerStage II cancerBilateral cancerIV cancerFemale sexIV diseaseReceptor-positiveExcellent prognosisII cancerClinical stageTumor typesTreated patientsStage IIICancerEvaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series
Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series. Cancers 2024, 16: 3050. PMID: 39272908, PMCID: PMC11394101, DOI: 10.3390/cancers16173050.Peer-Reviewed Original ResearchPlasmacytoid urothelial carcinomaMedian overall survivalNeoadjuvant chemotherapyUrothelial carcinomaOverall survivalTreatment patternsReceipt of neoadjuvant chemotherapyResponse to current therapiesCharacterize treatment patternsCox proportional hazards analysisEvaluate treatment patternsSite of metastasisProportional hazards analysisPT0 rateOS benefitHistological subtypesClinical stageCurrent therapiesInstitutional experiencePrimary outcomeNCDBTreatment trendsEffective treatmentPatientsCarcinomaImpact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer
Skelton W, Masur J, Thomas J, Fallah P, Jain R, Ravi P, Mantia C, McGregor B, Nuzzo P, Adib E, Zarif T, Preston M, Clinton T, Li R, Steele G, Kassouf W, Freeman D, Pond G, Jain R, Sonpavde G. Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. Clinical Genitourinary Cancer 2024, 22: 102143. PMID: 39032202, DOI: 10.1016/j.clgc.2024.102143.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerPathological complete responsePathologic complete response rateRenin-angiotensin systemNeoadjuvant chemotherapyAngiotensin-converting enzyme inhibitorsConverting enzyme inhibitorsOverall survivalRadical cystectomyPerformance statusClinical stageComplete responseBladder cancerAssociated with increased pCRAssociated with pathologic complete responseFemale sexAssociated with improved OSImpact of angiotensin-converting enzyme inhibitorsCycles of neoadjuvant chemotherapyMuscle invasive bladder cancerClinical stage of diseaseEnzyme inhibitorsAssociated with OSInitiation of therapyInvasive bladder cancerThe effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy
Lokeshwar S, Ali A, Weiss T, Reynolds J, Shuch B, Ferencz T, Kyriakides T, Mehal W, Brito J, Renzulli J, Leapman M. The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy. BMC Urology 2024, 24: 102. PMID: 38702664, PMCID: PMC11067086, DOI: 10.1186/s12894-024-01483-y.Peer-Reviewed Original ResearchConceptsEnd-of-studyProstate cancerRadical prostatectomyTreatment armsDouble-blind randomized trialProstate cancer characteristicsSurgical margin statusLocalized prostate cancerFACT-P scoresBaseline to end-of-studySerum PSACAPRA scoreGleason scorePSA levelsPlacebo-controlledMedium-chain triglyceridesPrimary endpointIntermediate riskClinical stageMargin statusSerum testosteroneRandomization armFACT-PRisk strataITT analysisThe International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer
Rami-Porta R, Nishimura K, Giroux D, Detterbeck F, Cardillo G, Edwards J, Fong K, Giuliani M, Huang J, Kernstine K, Marom E, Nicholson A, Van Schil P, Travis W, Tsao M, Watanabe S, Rusch V, Asamura H, Boards A. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer. Journal Of Thoracic Oncology 2024, 19: 1007-1027. PMID: 38447919, DOI: 10.1016/j.jtho.2024.02.011.Peer-Reviewed Original ResearchClassification of lung cancerLung cancerTNM classificationStage groupSignificance of survival differencesInternational Association for the Study of Lung CancerLung Cancer Staging ProjectTNM stage groupingTNM classification of lung cancerStudy of Lung CancerEdition TNMStage NSCLCPathological stageClinical stageSurvival differencesAnatomic extentTNMSurvival analysisTreatment approachesCancerStatistical significanceMultivariate regressionPatientsLungNCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024.
Schmults C, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, Bolotin D, Bordeaux J, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Ghosh K, Harms K, Ho A, Lukens J, Manber S, Mark L, Medina T, Nehal K, Nghiem P, Olino K, Park S, Patel T, Puzanov I, Rich J, Sekulic A, Shaha A, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu Y, Yu S, Yusuf M, McCullough B, Espinosa S. NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024. Journal Of The National Comprehensive Cancer Network 2024, 22: e240002. PMID: 38244274, DOI: 10.6004/jnccn.2024.0002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLocally advanced diseaseMerkel cell carcinomaAdvanced diseaseLocally advanced Merkel cell carcinomaAdvanced Merkel cell carcinomaNode negative statusSystemic therapy optionsIn-transit diseaseNCCN Guidelines InsightsCell carcinomaNCCN GuidelinesClinical stageDiagnostic workupTherapy optionsTreatment optionsNegative statusInstitutional reviewNCCNDiseaseGuidelinesOptionsCarcinomaWorkupPatientsPanel members
2023
Trends in access to minimally invasive pancreaticoduodenectomy for pancreatic cancers
Seldomridge A, Rasic G, Papageorge M, Ng S, de Geus S, Woods A, McAneny D, Tseng J, Sachs T. Trends in access to minimally invasive pancreaticoduodenectomy for pancreatic cancers. Hepato Pancreato Biliary 2023, 26: 333-343. PMID: 38087704, DOI: 10.1016/j.hpb.2023.11.012.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaNational Cancer DatabaseInvasive pancreaticoduodenectomySurgical approachNon-white patientsCochran-Armitage testMajority of operationsMedicare/Comorbidity statusClinical stageBlack raceCancer DatabaseLate diagnosisPancreatic cancerDuctal adenocarcinomaOpen approachSocial determinantsGovernment insurancePrivate insurancePatientsTechnologic advancesInsurance coverageMIPDPancreaticoduodenectomyFacility typeFactors associated with clinical trial participation for patients with renal cell carcinoma
Shinder B, Kim S, Srivastava A, Patel H, Jang T, Mayer T, Saraiya B, Ghodoussipour S, Singer E. Factors associated with clinical trial participation for patients with renal cell carcinoma. Urologic Oncology Seminars And Original Investigations 2023, 41: 208.e1-208.e8. PMID: 36868881, PMCID: PMC10106382, DOI: 10.1016/j.urolonc.2023.01.022.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCell carcinomaClinical trial participationClinical trialsOverall survivalClinical stageTrial patientsTrial participantsCharlson-Deyo comorbidity scoreAssociated with trial participationCompare overall survivalNational Cancer DatabaseLog-rank testClinical trial patientsPatient sociodemographic factorsAssociated with clinical trial participationMedian OSSuperior OSCancer DatabaseOncology clinical trialsSurvival outcomesMale patientsCase-control designPatient cohortControl cohortHBV-infected hepatocellular carcinoma can be robustly classified into three clinically relevant subgroups by a novel analytical protocol
Cheng Z, Li L, Zhang Y, Ren Y, Gu J, Wang X, Zhao H, Lu H. HBV-infected hepatocellular carcinoma can be robustly classified into three clinically relevant subgroups by a novel analytical protocol. Briefings In Bioinformatics 2023, 24: bbac601. PMID: 36736372, DOI: 10.1093/bib/bbac601.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaClinical stageImmune microenvironmentTumor sizeHepatitis B virus infectionLow alpha-fetoprotein levelsMetabolism-related proteinsRelevant subgroupsB virus infectionSevere liver dysfunctionGood liver functionHigh AFP levelsAlpha-fetoprotein levelsPrimary liver malignancySmaller tumor sizeLarger tumor sizeLower clinical stageHigher clinical stageCancer-related deathProliferation activityPrevention of HBVNear-normal levelsLow proliferation activityLiver dysfunctionHigh proliferation activity
2022
Concept of Further Decompensation and Recompensation
D’Amico G, Garcia-Tsao G. Concept of Further Decompensation and Recompensation. 2022, 523-535. DOI: 10.1007/978-3-031-08552-9_47.Peer-Reviewed Original ResearchRevisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Mase VJ, Dhanasopon AP, Boffa DJ. Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer. JTO Clinical And Research Reports 2022, 3: 100318. PMID: 35540711, PMCID: PMC9079298, DOI: 10.1016/j.jtocrr.2022.100318.Peer-Reviewed Original ResearchPrevalence of brainBrain metastasesSummary stageBrain imagingN classificationIsolated brain metastasesNode-negative NSCLCRoutine brain imagingStage II NSCLCStage IV NSCLCClinical stage INational Cancer DatabaseEarly-stage NSCLCStage IAStage IIIAStage NSCLCStaging evaluationClinical stageLung cancerCancer DatabaseN stageNSCLCPatientsStage IMetastasisSingle-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric CancerSingle-Cell Atlas of Gastric Cancer Subtypes
Kumar V, Ramnarayanan K, Sundar R, Padmanabhan N, Srivastava S, Koiwa M, Yasuda T, Koh V, Huang K, Tay S, Ho S, Tan A, Ishimoto T, Kim G, Shabbir A, Chen Q, Zhang B, Xu S, Lam K, Lum H, Teh M, Yong W, So J, Tan P. Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric CancerSingle-Cell Atlas of Gastric Cancer Subtypes. Cancer Discovery 2022, 12: 670-691. PMID: 34642171, PMCID: PMC9394383, DOI: 10.1158/2159-8290.cd-21-0683.Peer-Reviewed Original ResearchConceptsPatient-derived organoidsPlasma cell proportionsGastric cancer subtypesLineage statePredictors of poor clinical prognosisCancer subtypesSingle-cell atlasCell proportionCancer-associated fibroblasts' subtypesCell populationsDiffuse-type tumorsPoor clinical prognosisIn vivo modelsComprehensive single-cell atlasPrimary tumorHistological subtypesRNA-sequencing cohortsTumor microenvironmentClinical stageClinical prognosisGastric malignancyTumor ecosystemGastric cancerCancer heterogeneityTumor
2021
How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?
Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.Peer-Reviewed Original ResearchUse of NTNeoadjuvant therapyEarly pandemic periodBreast cancerNon-metastatic breast cancerPractice settingsEarly pandemicFlatiron Health databaseNeoadjuvant endocrine therapyTechnology-enabled abstractionSame period one yearSimilar clinicopathologic featuresLongitudinal electronic health recordsPeriod one yearElectronic health recordsTNBC subsetEndocrine therapyPatient ageTN patientsClinicopathologic featuresContemporary cohortClinical stageCancer clinicCancer managementHigh risk
2020
Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond
Srivastava A, Patel HV, Kim S, Shinder B, Sterling J, Tabakin AL, Polotti CF, Saraiya B, Mayer T, Kim IY, Ghodoussipour S, Patel HD, Jang TL, Singer EA. Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond. Urologic Oncology Seminars And Original Investigations 2020, 39: 247-257. PMID: 33223368, PMCID: PMC7574787, DOI: 10.1016/j.urolonc.2020.10.012.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaUpstaging riskOverall survivalCell carcinomaNonclear cell renal cell carcinomaOrgan-confined renal cell carcinomaCox proportional hazards modelNational Cancer DatabaseCell renal cell carcinomaKaplan-Meier curvesProportional hazards modelSmall renal massesCOVID-19Logistic regression modelsPT3a upstagingDelaying surgeryPrimary endpointSecondary endpointsPatient comorbiditiesMeier curvesElective surgeryRadical nephrectomyTumor histologyClinical stageRCC patientsAccuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival.
Srivastava A, Patel H, Kim S, Kim I, Singer E, Jang T. Accuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival. Journal Of Clinical Oncology 2020, 38: e17058-e17058. DOI: 10.1200/jco.2020.38.15_suppl.e17058.Peer-Reviewed Original ResearchRetroperitoneal lymph node dissectionNonseminomatous germ cell tumorsPrimary retroperitoneal lymph node dissectionCS I patientsNational Cancer DatabaseI patientsClinical stageOverall survivalClinical stagingTesticular nonseminomatous germ cell tumorsLymph node dissectionQuarter of patientsKaplan-Meier methodNodal disease burdenGerm cell tumorsUpstaging of diseaseCS1 patientsPathologic nodalPN3 diseasePrior chemotherapyNode dissectionIIA patientsMeier methodClinical outcomesTesticular cancerEfficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC): A National Cancer Database (NCDB) study.
Leone J, Freedman R, Hassett M, Leone J, Tolaney S, Vallejo C, Leone B, Winer E, Lin N. Efficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC): A National Cancer Database (NCDB) study. Journal Of Clinical Oncology 2020, 38: 587-587. DOI: 10.1200/jco.2020.38.15_suppl.587.Peer-Reviewed Original ResearchFemale breast cancerPathologic complete responseNeoadjuvant chemotherapyOverall survivalClinical responseTumor subtypesBreast cancerWorse OSExact testHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusEfficacy of NACInitiation of NACNational Cancer Database studyComplete clinical responseHormone receptor statusMale breast cancerLog-rank testFisher's exact testHR-/HER2Complete responseMedian ageReceptor statusMedian timeClinical stagePotent BRD4 inhibitor suppresses cancer cell-macrophage interaction
Yin M, Guo Y, Hu R, Cai WL, Li Y, Pei S, Sun H, Peng C, Li J, Ye R, Yang Q, Wang N, Tao Y, Chen X, Yan Q. Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction. Nature Communications 2020, 11: 1833. PMID: 32286255, PMCID: PMC7156724, DOI: 10.1038/s41467-020-15290-0.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnimalsCell CommunicationCell Cycle ProteinsCell Line, TumorCell ProliferationDisease Models, AnimalDown-RegulationDrug DesignFemaleHumansHypoxia-Inducible Factor 1, alpha SubunitMacrophage Colony-Stimulating FactorMacrophagesMice, Inbred BALB CMice, NudeNeoplasmsPhosphorylationProto-Oncogene Proteins c-mycReceptors, Granulocyte-Macrophage Colony-Stimulating FactorSignal TransductionTranscription FactorsTreatment OutcomeConceptsTumor growthMajor clinical stagesBET inhibitorsProliferation of tumorsExtraterminal domain (BET) family proteinsTumor cell proliferationClinical stageTumor shrinkageSyngeneic modelPotent BRD4 inhibitorsSmall molecule inhibitorsSolid tumorsBRD4 inhibitionTumor cellsOral bioavailabilityCancer treatmentCell proliferationBRD4 inhibitorsMolecule inhibitorsMultiple mechanismsC-MycTumorsInhibitors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply